West Branch Capital’s CRISPR Therapeutics CRSP Stock Holding History

West Branch Capital’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-50	Closed	-$2.7K	–	629
2024 Q2	$2.7K	Hold	50	–	–	﹤0.01%	368
2024 Q1	$3.41K	Hold	50	–	–	﹤0.01%	357
2023 Q4	$3.13K	Hold	50	–	–	﹤0.01%	375
2023 Q3	$2.27K	Hold	50	–	–	﹤0.01%	385
2023 Q2	$2.81K	Hold	50	–	–	﹤0.01%	383
2023 Q1	$2.26K	Hold	50	–	–	﹤0.01%	392
2022 Q4	$2.03K	Hold	50	–	–	﹤0.01%	390
2022 Q3	$3K	Hold	50	–	–	﹤0.01%	383
2022 Q2	$3K	Hold	50	–	–	﹤0.01%	365
2022 Q1	$3K	Hold	50	–	–	﹤0.01%	378
2021 Q4	$4K	Hold	50	–	–	﹤0.01%	396
2021 Q3	$6K	Hold	50	–	–	﹤0.01%	339
2021 Q2	$8K	Buy	+50	New	+$6.08K	﹤0.01%	337

Other funds holding CRSP

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

West Branch Capital's CRSP Position: Q3 2024 in Review

West Branch Capital sold out of CRISPR Therapeutics (CRSP) in Q3 2024, closing a stake of 50 shares — an estimated $2.7K sold.

West Branch Capital first reported a position in CRSP in Q2 2021 and held it in 13 quarters. The position peaked at $8K in Q2 2021. 416 funds tracked by Wall St. Rank hold CRSP as of Q3 2024.

West Branch Capital reported no remaining CRISPR Therapeutics position as of Q3 2024 after selling out during the quarter.
West Branch Capital sold 50 CRISPR Therapeutics shares in Q3 2024, an estimated $2.7K.
West Branch Capital first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 13 quarters.
West Branch Capital's CRISPR Therapeutics position peaked at $8K in Q2 2021.
416 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2024.

Based on West Branch Capital's 13F filing for Q3 2024, filed 18 Oct 2024.